04 March 2023 : Clinical Research
Perfusate Neutrophil Gelatinase-Associated Lipocalin, Kidney Injury Molecular-1, Liver-Type Fatty Acid Binding Protein, and Interleukin-18 as Potential Biomarkers to Predict Delayed Graft Function and Long-Term Prognosis in Kidney Transplant Recipients: A Single-Center Retrospective Study
Zejia Sun1AEF, Zihao Gao1ACE, Xin Li1ABC, Xiang Zheng1BD, Wei Wang1AEG*, Peng Qiao1AEFDOI: 10.12659/MSM.938758
Med Sci Monit 2023; 29:e938758
Table 1 Kidney transplant recipient characteristics.
| Characteristic | ALL (n=102) | DGF (n=14) | NON-DGF (n=88) | P valuea | |
|---|---|---|---|---|---|
| Age, yr | 43.36±12.07 | 39.97±11.28 | 43.90±12.17 | 0.260 | |
| Male | 70 (68.6) | 13 (92.9) | 57 (64.8) | 0.059 | |
| BMI, kg/m | 23.32±3.77 | 23.10±5.19 | 23.36±3.53 | 0.857 | |
| Hypertension | 94 (92.2) | 11 (78.6) | 83 (94.3) | 0.077 | |
| Diabetes | 16 (15.7) | 1 (7.1) | 15 (17.0) | 0.691 | |
| Cause of ESRD | Glomerulonephritis | 50 (49.0) | 7 (50.0) | 43 (48.9) | 0.976 |
| Hypertension | 16 (15.7) | 2 (14.3) | 14 (15.9) | ||
| Diabetes | 12 (11.8) | 1 (7.1) | 11 (12.5) | ||
| Polycystic kidney | 6 (5.9) | 1 (7.1) | 5 (5.7) | ||
| Other or unknown | 18 (17.6) | 3 (21.4) | 15 (17.0) | ||
| HLA mismatch level | 0 | 2 (2.0) | 0 (0.0) | 2 (2.3) | 0.044 |
| 1 | 5 (4.9) | 0 (0.0) | 5 (5.7) | ||
| 2 | 7 (6.9) | 0 (0.0) | 7 (8.0) | ||
| 3 | 20 (19.6) | 1 (7.1) | 19 (21.6) | ||
| 4 | 32 (31.4) | 2 (14.3) | 30 (34.1) | ||
| 5 | 19 (18.6) | 5 (35.7) | 14 (15.9) | ||
| 6 | 17 (16.7) | 6 (42.9) | 11 (12.5) | ||
| Panel reactive antibody | 0% | 65 (63.7) | 9 (64.3) | 56 (63.6) | 0.449 |
| 1–10% | 6 (5.9) | 2 (14.3) | 4 (4.5) | ||
| 11–80% | 17 (16.7) | 2 (14.3) | 15 (17.0) | ||
| >80% | 14 (13.7) | 1 (7.1) | 13 (14.8) | ||
| Warm ischemia time, min | 2.68±0.06 | 2.64±0.17 | 2.68±0.06 | 0.754 | |
| Cold ischemia time, h | 6.71±1.92 | 8.33±1.70 | 6.42±1.79 | <0.001 | |
| Serum creatinine at transplant, mg/dl | 8.97±3.06 | 10.05±2.80 | 8.80±3.08 | 0.155 | |
| Chronic dialysis before transplant | 82 (80.4) | 13 (92.9) | 69 (78.4) | 0.292 | |
| Allograft weight, g | 145.53±22.75 | 149.00±14.94 | 144.98±23.78 | 0.542 | |
| Perfusion time, min | 27.65±1.45 | 28.00±1.11 | 27.59±1.49 | 0.309 | |
| Immune inducer | ATG | 49 (48.0) | 8 (57.1) | 41 (46.6) | 0.264 |
| Basiliximab | 50 (49.0) | 5 (35.7) | 45 (51.1) | ||
| ATG+ Basiliximab | 3 (2.9) | 1 (7.1) | 2 (2.3) | ||
| immunosuppressor | TAC+MMF+PAT | 97 (95.1) | 14 (100.0) | 83 (94.3) | 0.470 |
| CSA+MMF+PAT | 5 (4.9) | 0 (0.0) | 5 (5.7) | ||
| Values reported are the mean±SD, n(%), or as otherwise indicated. a Wilcoxon rank-sum test or test was used for the continuous variables, and the chi-squared or Fisher exact tests were used for the categorical variables. BMI – body mass index; ERSD – end-stage renal disease; HLA – human leukocyte antigen; ATG – antithymocyte globulin; TAC – tacrolimus; MMF – mycophenolate mofetil; CSA – cyclosporine; Pred – prednisone; DGF – delayed graft function. | |||||